New combo shows promise against tough skin cancer
NCT ID NCT05309421
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether adding an experimental drug (EVX-01) to standard immunotherapy (pembrolizumab) can shrink tumors better than pembrolizumab alone in people with advanced melanoma that cannot be removed by surgery. Seventeen adults who have never received checkpoint inhibitors are being treated and followed for up to two years. The main goal is to see if the combination improves the overall response rate compared to historical data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EVX-01 (investigational drug) plus pembrolizumab (Keytruda)
What this could lead to
If successful, this combination could improve tumor shrinkage and delay cancer progression in people with advanced melanoma who haven't had checkpoint inhibitor therapy.
What could go wrong
This is a small, early-phase trial with only 17 participants and no comparison group. Results may not apply to all patients, and the combination could cause added side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Divisione di Oncologia Medica del Melanoma
Milan, Italy
-
Instituto Nazionale Tumori IRCCS Fondazione
Naples, Italy
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2065, Australia
-
One Clinical Research
Nedlands, Western Australia, 6009, Australia